Find disease awareness content and relevant supporting materials

Follow all the latest developments with daily highlights from the European Society of Medical Oncology Breast Cancer Congress in Berlin, Germany, 3–5 May 2022.

The European Society for Medical Oncology (ESMO) has issued expert consensus statements on managing breast cancer during pregnancy (PrBC), a rare and complex clinical scenario. These recommendations, developed through a multidisciplinary process, aim to balance maternal treatment needs with fetal safety in the absence of randomized trial data.

Astellas Pharma Inc. announced dosing of the first patient in the HIGHLIGHT 1 Phase III pivotal study for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) in women with breast cancer receiving adjuvant endocrine therapy

Join Professor Nadia Harbeck, Director of the Breast Centre at LMU University Hospital in Munich, Germany, as she shares her insights on the key developments for breast cancer treatment that emerged at ESMO Breast Cancer 2022.

The European Society for Medical Oncology (ESMO) has released expert consensus statements on HER2-low breast cancer, a newly recognized and targetable subtype. These statements address biology, diagnosis, treatment, and clinical trial design, aiming to guide oncologists in managing HER2-low metastatic disease.

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Keytruda (pembrolizumab) from Merck Sharp & Dohme for triple negative breast cancer.

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Enhertu. The marketing authorisation holder for this medicinal product is Daiichi Sankyo Europe GmbH and licensee is AstraZeneca

NICE (National Institute for Health and Care Excellence (UK)recommended Trodelvy (also called sacituzumab govitecan and made by Gilead Sciences) for treating locally advanced or metastatic triple negative breast cancer which cannot be removed surgically.

The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Verzenios (abemaciclib)(Verzenio in the US), from Eli Lilly. The CHMP adopted an extension to the existing indication to include use in early breast cancer at high risk of recurrence.

In the last 30 years or so there has been increased attention on the medical uses of cannabis and its constituent chemicals. Cannabis itself contains at least 60 active cannabinoids, one of which, cannabidiol (CBD)...